Currently out of the existing stock ratings of Kelly Shi, 38 are a BUY (90.48%), 4 are a HOLD (9.52%).

Kelly Shi

Work Performance Price Targets & Ratings Chart

Analyst Kelly Shi, currently employed at JEFFERIES, carries an average stock price target met ratio of 53.13% that have a potential upside of 29.21% achieved within 180 days.

Kelly Shi’s has documented 84 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 24-Jun-2025.

Wall Street Analyst Kelly Shi

Analyst best performing recommendations are on IMAB (I-MAB).
The best stock recommendation documented was for MLTX (MOONLAKE IMMUNOTHERAPEUTICS) at 6/26/2023. The price target of $58 was fulfilled within 22 days with a profit of $12.05 (26.22%) receiving and performance score of 11.92.

Average potential price target upside

of $47.44 (34.4%) on ASND (ASCENDIS PHARMA AS).
of $13.01 (45.18%) on PTCT (PTC THERAPEUTICS).
of $11.7 (17.54%) on INCY (YTE).

HGEN Humanigen IMGN ImmunoGen KYMR Kymera Therapeutics MLTX MoonLake Immunotherapeutics IBRX Immunitybio ACET Adicet Bio PTCT PTC Therapeutics ADAG Adagene ASND Ascendis Pharma AS CNTA Centessa Pharmaceuticals PLC ADR FHTX Foghorn Therapeutics INCY yte TIL Instil Bio IMAB I-Mab PROK ProKidney Corp. ALDX Aldeyra The

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Tiago Fauth (CREDIT SUISSE)